T2 Biosystems to Participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum
November 09 2022 - 4:05PM
T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid
detection of sepsis-causing pathogens and antibiotic resistance
genes, today announced plans to participate in the upcoming
Canaccord Genuity MedTech, Diagnostics and Digital Health &
Services Forum in New York, New York.
Management is scheduled to present on Thursday, November 17,
2022, at 2pm ET. Interested parties may access a live and recorded
webcast of the presentation on the “Investors” section of the
Company’s website at www.t2biosystems.com.
About T2 BiosystemsT2 Biosystems, a leader
in the rapid detection of sepsis-causing pathogens and antibiotic
resistance genes, is dedicated to improving patient care and
reducing the cost of care by helping clinicians effectively treat
patients faster than ever before. T2 Biosystems’ products include
the T2Dx® Instrument, the T2Bacteria® Panel, the T2Candida® Panel,
the T2Resistance® Panel, and the T2SARS-CoV-2™ Panel and are
powered by the proprietary T2 Magnetic Resonance (T2MR®)
technology. T2 Biosystems has an active pipeline of future
products, including the T2Biothreat™ Panel, the T2Cauris™ Panel,
and T2Lyme™ Panel, as well as next-generation products for the
detection of bacterial and fungal pathogens and associated
antimicrobial resistance markers.
Investor Contact:Philip Trip Taylor, Gilmartin
Groupphilip@gilmartinIR.com 415-937-5406
T2 Biosystems (NASDAQ:TTOO)
Historical Stock Chart
From Mar 2024 to Apr 2024
T2 Biosystems (NASDAQ:TTOO)
Historical Stock Chart
From Apr 2023 to Apr 2024